Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466921 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
A Phase 2 study of Lymphoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT00466921 is a Phase 2 study of Lymphoma that has completed, run by Northwestern University. The registered enrollment target is 33 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00466921, a Phase 2 study of Lymphoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.
Conditions Studied
Interventions
- DRUG lenalidomide
Study Locations (3)
California
- Stanford Cancer Center - Stanford
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-04-19 |
| Est. Completion | 2013-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466921
The ClinicalTrials.gov registry entry for NCT00466921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which lenalidomide is the first listed.
NCT00466921 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT00466921 about?
NCT00466921 is a clinical study titled "Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome". RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.
What is the current status of trial NCT00466921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2005-04-19. Estimated completion is 2013-05-17.
What conditions does trial NCT00466921 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00466921?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00466921?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466921 being conducted?
This trial has 3 study locations across California, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.